Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate "agonist" medications for cocaine dependence: Studies in assays of cocaine discrimination and cocaine self-administration in rhesus monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 2, 2007, Pages 627-636

  Negus, S S ^a   Mello, N K ^a   Blough, B E ^b   Baumann, M H ^c   Rothman, R B ^c  

^a MCLEAN HOSPITAL   (United States)

^b RTI INTERNATIONAL   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; COCAINE; DOPAMINE; FENFLURAMINE; METHAMPHETAMINE; NORADRENALIN; PAL 287; PAL 314; PAL 353; SEROTONIN; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG DEPENDENCE TREATMENT; DRUG DISCRIMINATION; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; MONOAMINE RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RHESUS MONKEY; SEROTONIN RELEASE;

ANIMALS; COCAINE; COCAINE-RELATED DISORDERS; DISCRIMINATION LEARNING; DOPAMINE; MACACA MULATTA; MALE; NOREPINEPHRINE; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; SEROTONIN;

EID: 33846451025     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.107383     Document Type: Article

References (34)

1. Carroll FI, Howell LL, and Kuhar MJ (1999) Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J Med Chem 42:2721-2736.
2. Chait LD, Uhlenhuth EH, and Johanson CE (1986) The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology (Berl) 89:301-306.
3. Czoty PW, Ginsburg BC, and Howell LL (2002) Serotonergic attenuation of the reinforcing and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 300:831-837.
4. D'Mello GD and Stolerman IP (1977) Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats. Br J Pharmacol 61:415-422.
5. Glowa JR, Rice KC, Matecka D, and Rothman RB (1997) Phentermine/ fenfluramine decreases cocaine self-administration in rhesus monkeys. Neuroreport 8:1347-1351.
6. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, and Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522-526.
7. Grabowski J, Shearer J, Merrill J, and Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav 29:1439-1464.
8. Higgins GA and Fletcher PJ (2003) Serotonin and drug reward: focus on 5-HT2C receptors. Eur J Pharmacol 480:151-162.
9. Lamas X, Negus SS, Nader MA, and Mello NK (1996) Effects of the putative dopamine D3 receptor agonist 7-OH-DPAT in rhesus monkeys trained to discriminate cocaine from saline. Psychopharmacology (Berl) 124:306-314.
10. Locke KW, Levesque TR, Nicholson KL, and Balster RL (1996) Dexfenfluramine lacks amphetamine-like abuse potential. Prog Neuropsychopharmacol Biol Psychiatry 20:1019-1035.
11. Mello NK (2005) Fischman Memorial Lecture. Evaluation of drug abuse treatment medications: concordance between clinical and preclinical studies. NIDA Res Monogr 185:82-104.
12. Mello NK and Negus SS (1996) Preclinical evaluation of pharmacotherapies for treatment of cocaine and opioid abuse using drug self-administration procedures. Neuropsychopharmacology 14:375-424.
13. Mello NK and Negus SS (1998) Effects of kappa opioid agonists on cocaine- and food-maintained responding by rhesus monkeys. J Pharmacol Exp Ther 286:812-824.
14. Mendelson JH and Mello NK (2004) Cocaine and other commonly abused drugs, in Harrison's Principles of Internal Medicine, 16th ed. (Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, and Jameson JL eds) pp 2570-2573, McGraw-Hill Book Companies, New York.
15. Negus SS (2003) Rapid assessment of choice between cocaine and food in rhesus monkeys: effects of environmental manipulations and treatment with d-amphetamine and flupenthixol. Neuropsychopharmacology 28:919-931.
16. Negus SS, Brandt MR, and Mello NK (1999) Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther 291:60-69.
17. Negus SS and Mello NK (2002) Effects of μ-opioid agonists on cocaine- and food-maintained responding and cocaine discrimination in rhesus monkeys: role of μ-agonist efficacy. J Pharmacol Exp Ther 300:1111-1121.
18. Negus SS and Mello NK (2003a) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a progressive-ratio schedule in rhesus monkeys. Psychopharmacology (Berl) 167:324-332.
19. Negus SS and Mello NK (2003b) Effects of chronic d-amphetamine treatment on cocaine- and food-maintained responding under a second-order schedule in rhesus monkeys. Drug Alcohol Depend 70:39-52.
20. Negus SS, Mello NK, Portoghese PS, and Lin CE (1997) Effects of κ-opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282:44-55.
21. Newman AH and Kulkarni S (2002) Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic - a focus on analogues of benztropine and rimcazole. Med Res Rev 22:429-464.
22. Oliveto AH, McCance-Katz E, Singha A, Hameedi F, and Kosten TR (1998) Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behav Pharmacol 9:207-217.
23. Peltier RL, Li DH, Lytle D, Taylor CM, and Emmett-Oglesby MW (1996) Chronic d-amphetamine or methamphetamine produces cross-tolerance to the discriminative and reinforcing stimulus effects of cocaine. J Pharmacol Exp Ther 277:212-218.
24. Pereira Do Carmo G, Mello NK, Rice KC, and Negus SS (2006) Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol 547:92-100.
25. Platt DM, Rowlett JK, and Spealman RD (2002) Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 163:265-282.
26. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41.
27. Rothman RB, Blough BE, and Baumann MH (2002) Appetite suppressants as agonist substitution therapies for stimulant dependence. Ann NY Acad Sci 965:109-126.
28. Rothman RB, Blough BE, Woolverton WL, Anderson KG, Negus SS, Mello NK, Roth BL, and Baumann MH (2005) Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther 313:1361-1369.
29. Rothman RB and Glowa JR (1995) A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development: focus on GBR 12909. Mol Neurobiol 10:1-19.
30. Schuster CR and Johanson CE (1985) Efficacy, dependence potential and neurotoxicity of anorectic drugs, in Behavioral Pharmacology: The Current Status (Seiden LS and Balster RL eds) pp 263-279, Alan R. Liss, Inc., New York.
31. Vocci FJ, Acri J, and Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatry 162:1432-1440.
32. Wee S, Anderson KG, Baumann MH, Rothman RB, Blough BE, and Woolverton WL (2005) Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs. J Pharmacol Exp Ther 313:848-854.
33. Wood DM and Emmett-Oglesby MW (1988) Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology (Berl) 95:364-368.
34. Woolverton WL and Johnson KM (1992) Neurobiology of cocaine abuse. Trends Pharmacol Sci 13:193-200.